PNPLA3 and metabolic dysfunction-associated steatohepatitis: Individuals with SLD who possess the PNPLA3 I148M variant, resulting in an isoleucine to methionine substitution at the amino acid position 148 (PNPLA3 I148M), have a 220% higher likelihood of developing fibrosis and a 248.8% higher likelihood of developing MASH compared to those without the variant [14].